IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: Clinical studies from Phase I and Phase II trials with imatinib in patients, suffering from chronic myeloid leukemia (CML) with interferon (IFN) resistance or from advanced Philadelphia chromosome-positive leukemias showed antitumor activity.